Mini Review

Incidence of symptom-driven Coronary Angiographic procedures post-drug-eluting Balloon treatment of Coronary Artery drug-eluting stent in-stent Restenosis-does it matter?

Victor Voon*, Dikshaini Gumani, Calvin Craig, Ciara Cahill, Khalid Mustafa, Terry Hennessy, Samer Arnous and Thomas Kiernan

Published: 29 June, 2017 | Volume 2 - Issue 1 | Pages: 035-041

Objectives: The clinical impact of drug-eluting balloon (DEB) coronary intervention for drug-eluting in-stent restenosis (DES-ISR) is not fully known. To further evaluate this impact, we aimed to describe the incidence of symptom-driven coronary angiography (SDCA), an under-reported but potentially informative outcome metric in this cohort of patients. Methods: We retrospectively identified all patients (n=28) who had DEB-treated DES-ISR at University Hospital Limerick in between 2013-2015 and evaluated the incidence of subsequent SDCA as the primary endpoint. Data were expressed as mean ± SD and %. Results: Baseline demographics demonstrate a mean age 63±9 years with 61% of DEB-treated DES-ISR presenting with acute coronary syndrome. Mean number of ISR per patient and number of DEB per lesion was 1.2±0.6 lesions and 1.2±0.6 balloons, respectively. The incidence of SDCA was 54% after mean follow-up duration of 179±241 days. 67.8% of patients had follow-up data beyond 12 months. Within the first year of follow-up, the incidence of SDCA with and without target lesion revascularization (TLR) was 11% and 36% respectively. Among patients with SDCA without TLR, 30% had an acute coronary syndrome not requiring percutaneous coronary intervention. Conclusions: A high incidence of SDCA was observed, particularly within the first 12 months after DEB-treated DES-ISR. This under-reported metric may represent a cohort at higher cardiovascular risk but requires further confirmation in larger studies.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001011 Cite this Article Read Full Article PDF


  1. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010; 56: 1897-1907. Ref.: https://goo.gl/i2K8Ux
  2. Kolh P, Windecker S. ESC/EACTS myocardial revascularization guidelines 2014. Eur Heart J. 2014; 35: 3235-3236. Ref.: https://goo.gl/oMwtxJ
  3. Cassese S, Byrne RA, Schulz S, Hoppman P, Kreutzer J, et al. Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. Eur Heart J. 2015; 36: 94-99. Ref.: https://goo.gl/kA6ux6
  4. Auffret V, Berland J, Barragan P, Waliszewski M, Bonello L, et al. Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry. Int J Cardiol. 2016; 203: 690-696. Ref.: https://goo.gl/bYnMgT
  5. Habara S, Kadota K, Shimada T, Ohya M, Amano H, et al. Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis. J Am Coll Cardiol. 2015; 66: 14-22. Ref.: https://goo.gl/nfTbAW
  6. Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol. 2012; 59: 1377-1382. Ref.: https://goo.gl/PPmyrE
  7. Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff Bet, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013; 381: 461-467. Ref.: https://goo.gl/rL6SRN
  8. Xu B, Gao R, Wang J, Yang Y1, Chen S, et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014; 7: 204-211. Ref.: https://goo.gl/uKAZDD
  9. Lee JM, Park J, Kang J, Jeon KH, Jung JH, et al. Comparison among drug-eluting balloon, drug-eluting stent, and plain balloon angioplasty for the treatment of in-stent restenosis: a network meta-analysis of 11 randomized, controlled trials. JACC Cardiovasc Interv. 2015; 8: 382-394. Ref.: https://goo.gl/aYJr8o
  10. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999; 100: 1872-1878. Ref.: https://goo.gl/q6UMhf
  11. Habara S, Iwabuchi M, Inoue N, Nakamura S, Asano R, et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J. 2013; 166: 527-533. Ref.: https://goo.gl/tJcVJE
  12. Ito S, Nakasuka K, Morimoto K, Inomata M, Yoshida T, et al. Angiographic and clinical characteristics of patients with acetylcholine-induced coronary vasospasm on follow-up coronary angiography following drug-eluting stent implantation. J Invasive Cardiol. 2011; 23: 57-64. Ref.: https://goo.gl/3B6mf8


Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More